SPD489

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaMajor Depressive DisorderEating DisorderExecutive Function

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

SPD489

Takeda

Approved

62

Ozempic

Novo Nordisk

Preclinical

13

Resotran

Takeda

Preclinical

14

Lunesta

Akero Therapeutics

Preclinical

35

Comtan

Orion Corporation, Orion Pharma

Preclinical

16

Permax

VValeant Pharmaceuticals

Preclinical

17

Luvox

SSolvay Pharmaceuticals

Preclinical

18

Persantine

Boehringer Ingelheim

Preclinical

19

Inversine

TTargacept Inc.

Preclinical

110

Pitressin

AAultman Health Foundation

Preclinical

—Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia6 trials

SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia

Withdrawn·Takeda·Phase 3·NCT01234298

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Terminated·Takeda·Phase 3·NCT01760889·1 enrolled

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Terminated·Takeda·Phase 3·NCT01760993·2 enrolled

Show 3 more trials

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Completed·Takeda·Phase 1·NCT01457339·31 enrolled

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Completed·Takeda·Phase 2·NCT00922272·92 enrolled

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

Terminated·Takeda·Phase 3·NCT01738698·4 enrolled

Attention Deficit Hyperactivity Disorder5 trials

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Completed·Takeda·Phase 3·NCT03260205·199 enrolled

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Completed·Takeda·Phase 4·NCT00877487·123 enrolled

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

Completed·Takeda·Phase 2·NCT02402166·24 enrolled

Show 2 more trials

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Withdrawn·Takeda·Phase 3·NCT01274221

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Completed·Takeda·Phase 3·NCT02466386·113 enrolled

Major Depressive Disorder3 trials

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Terminated·Takeda·Phase 3·NCT01436175·1,570 enrolled

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Completed·Takeda·Phase 2·NCT00985725·143 enrolled

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Completed·Takeda·Phase 3·NCT01436149·1,262 enrolled

Eating Disorder2 trials

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Completed·Takeda·Phase 3·NCT01718509·390 enrolled

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Completed·Takeda·Phase 3·NCT01718483·383 enrolled

Adult1 trial

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

Completed·Takeda·Phase 2·NCT01096680·135 enrolled

1 more indication

Executive Function1 trial

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed·Takeda·Phase 4·NCT01101022·161 enrolled

Details

Drug Info

Related News